← Back to Search

Extracellular Vesicles

Stem Cell-Derived Therapy for Burns

Phase 1
Recruiting
Research Sponsored by Aegle Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Index burn injury within the prior 48 hours
Eighteen years of age or older with deep second degree thermal burn wounds
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial studies the use of stem cells to treat deep skin burns, to reduce scarring and improve healing.

Who is the study for?
Adults with deep second-degree thermal burns covering a total area less than 300 cm2, sustained within the last 24 hours. Participants must be able to attend treatment sessions and agree to contraception if applicable. Excluded are those with burns over scars, expected quick healing, infections at wound site, certain medical conditions including severe coagulopathy or cardiopulmonary disease, substance abuse history within a year, life expectancy under two years, specific blood count abnormalities, allergy to human albumin or certain antibiotics.Check my eligibility
What is being tested?
The trial is testing AGLE-102 extracellular vesicles from bone marrow stem cells on patients with serious burn wounds. The goal is to see if these vesicles can help heal the skin better than current treatments. Patients will receive this new therapy directly on their wounds and will be monitored for effectiveness and safety.See study design
What are the potential side effects?
Potential side effects of AGLE-102 may include local reactions at the application site such as redness or irritation. Since it's a biological product derived from stem cells there might also be risks of immune reactions or infection transmission although specifics aren't provided.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My burn injury happened within the last 2 days.
Select...
I am 18 or older with deep second-degree burns.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Examine the safety of applying up to three applications of EVs to deep 2nd degree burn wounds up to 600 cm2
Secondary outcome measures
Determine if administration of EVs can promote wound healing by serial wound measurements
Laser Doppler will assess differences in dermal perfusion rates between control (unburned) and treated burn tissues.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AGLE-102Experimental Treatment1 Intervention
AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)

Find a Location

Who is running the clinical trial?

Aegle TherapeuticsLead Sponsor
1 Previous Clinical Trials
10 Total Patients Enrolled
Congressionally Directed Medical Research ProgramsFED
48 Previous Clinical Trials
6,766 Total Patients Enrolled

Media Library

Mesenchymal Stem Cell Extracellular Vesicles (Extracellular Vesicles) Clinical Trial Eligibility Overview. Trial Name: NCT05078385 — Phase 1
Burns Research Study Groups: AGLE-102
Burns Clinical Trial 2023: Mesenchymal Stem Cell Extracellular Vesicles Highlights & Side Effects. Trial Name: NCT05078385 — Phase 1
Mesenchymal Stem Cell Extracellular Vesicles (Extracellular Vesicles) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05078385 — Phase 1
~6 spots leftby Jun 2025